Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Microplastics in humans: first look at how they travel inside us

NCT ID NCT07075991

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study gave 6 healthy adults a single tiny dose of labeled microplastics to track how much gets absorbed into the blood and how it leaves the body through urine and stool. Participants provided samples over 5 days. The goal is to understand basic movement of microplastics in humans, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
1 μm [14C]-labelled polystyrene microplastic particles
What this could lead to
If successful, this could reveal how much microplastic enters the bloodstream and how the body clears it, informing future health risk assessments.
What could go wrong
This is a very small, early-stage study with only 6 participants and no comparison group. Results may not apply to larger populations or different microplastic types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Jun 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males and females using contraception during and for 3 months after the study. * Aged from 18-65 years at the time of signing informed consent * 18.5 \< BMI \< 25 kg·m-2 * Must be willing and able to communicate and participate in the whole study * Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * Diabetes (Type 1, Type 2, or genetic form of diabetes) * Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or ≥90 mmHg diastolic) * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastro-intestinal disease, immunodeficiency, endocrine, neurological or psychiatric disorders * Known severe kidney problems * Subjects who have regular gastrointestinal complaints including abdominal pain, stomach upsets and borborygmi, known or suspected irritable bowel syndrome, or functional constipation * Recent or chronic history of diarrhoea * Known anaemia * Known impaired liver function * A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia. * Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) * History of any drug or alcohol abuse in the past two years * A confirmed positive alcohol breath test at screening or admission * Any known food allergies or intolerances to the 14 major food allergens (celery, cereals containing gluten, crustaceans, eggs, fish, lupin, milk, molluscs, mustard, tree nuts, peanuts, sesame seeds, soybeans, sulphur dioxide and sulphites) or history of a malabsorption syndrome including coeliac disease * Currently taking part in other scientific research * Having received a product with 14C in the past 12 months * Pregnant or breastfeeding * Subjects who have taken antibiotics within the 60 days prior to the adaptation period. * Unable to give consent * Employed or undertaking a thesis or internship at the department of Human and Animal Physiology

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kinetics are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wageningen University, Department of Human and Animal Physiology

    Wageningen, 6708 WD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.